Mallinckrodt Pharmaceuticals

August 7, 2018

NET DEBT LEVERAGE RATIO (NON-GAAP FINANCIAL MEASURE)

Mallinckrodt plc and its subsidiaries (collectively, "the company") may from time to time reference net debt leverage ratio in its public communications, which is considered a "non-GAAP" financial measure under applicable U.S. Securities and Exchange Commission rules and regulations.

Net debt leverage ratio is a key financial measure that is used by management to assess the borrowing capacity of the company. The company has defined its net debt leverage ratio as net debt (total principal debt outstanding less unrestricted cash) divided by adjusted EBITDA for the trailing twelve month period. Adjusted EBITDA for purposes of the net debt leverage ratio represents net income (loss), prepared in accordance with accounting principles generally accepted in the U.S. ("GAAP"), adjusted for interest expense, taxes, depreciation and amortization, certain items that management believes are not reflective of the operational performance of the business and additional adjustments as allowable under the company's credit facility. These adjustments include, but are not limited to, non-restructuring impairment charges; restructuring and related charges, net; inventory step-up expense; discontinued operations; changes in fair value of contingent consideration obligations; acquisition-related expenses; historical EBITDA of companies acquired during the period; and other items identified by the company.

This adjusted measure should be considered supplemental to and not a substitute for financial information prepared in accordance with GAAP. The company's definition of this adjusted measure may differ from similarly titled measures used by others or similar metrics used by the company for debt covenant compliance.

Because adjusted financial measures exclude the effect of items that will increase or decrease the company's reported results of operations, Mallinckrodt strongly encourages investors to review the company's consolidated financial statements and publicly filed reports in their entirety. A reconciliation of the net debt leverage ratio to GAAP net (loss) income is included in the following table.

NET DEBT LEVERAGE RATIO [1]:

		Twelve Months Ended June 29, 2018
Total debt	$	6,430.6
Less: Unrestricted cash		235.7
Net debt	**$**	**6,194.9**
GAAP Net Income (Loss):		
Six months ended June 29, 2018	$	(2.4)
Plus: Twelve months ended December 30, 2017		2,134.4
Less: Six months ended June 30, 2017		462.0
Twelve months ended June 29, 2018		1,670.0
Trailing twelve months adjustments:		
Interest expense		369.2
Income taxes		(1,791.2)
Depreciation		49.9
Intangible asset amortization		698.6
Non-restructuring impairment		63.7
Restructuring and related charges, net		96.4
Inventory step-up expense		52.7
Discontinued operations [2]		130.5
Change in fair value of contingent consideration obligations		(70.7)
Acquisition-related expenses		9.4
Gain on divestiture		0.4
Historical EBITDA of companies acquired		56.7
Non-cash stock compensation expense		40.9
Other (expense) income, net		(5.1)
Other credit facility addbacks		20.1
Adjusted EBITDA	**$**	**1,391.5**
Net Debt Leverage Ratio:		**4.5**

(1) The Net Debt Leverage Ratio is calculated in accordance with the company's Credit Agreement dated as of March 19, 2014 (as amended, restated, supplemented or otherwise modified) and used for the purpose of testing the financial covenant in Section 6.12 of this agreement.

(2) Discontinued operations is comprised of income from discontinued operations of $93.0 million, net of adjusted EBITDA from the specialty generics disposal group of $223.5 million as the consummation of this disposition has not yet occurred.